glp 1 drugs and inflammation The anti-inflammatory immunological properties of GLP-1 Receptor Agonists Frontiers | GLP-1 RAs and

A population-based study from Scandinavia provides some real-world information.

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

This innovative oral GLP-1 is a small molecule medication that, unlike the Wegovy pill, doesnt require that you take it on an empty stomach.

Our preclinical findings highlight its potential therapeutic use for patients

Satiety regulation (reduces appetite, aiding in weight loss)

Furthermore,...